Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.
作者信息
White N J
机构信息
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
出版信息
Antimicrob Agents Chemother. 1997 Jul;41(7):1413-22. doi: 10.1128/AAC.41.7.1413.
Abstract
摘要
相似文献
1
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.体内抗疟药物药效学特性评估。
Antimicrob Agents Chemother. 1997 Jul;41(7):1413-22. doi: 10.1128/AAC.41.7.1413.
2
Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo.在体研究抗疟药物对鼠体血期疟原虫成熟和清除的影响。
Int J Parasitol. 2017 Dec;47(14):913-922. doi: 10.1016/j.ijpara.2017.05.009. Epub 2017 Aug 31.
3
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.通过定量PCR评估抗疟药物在临床试验中的药效学作用。
Antimicrob Agents Chemother. 2015 Jul;59(7):4249-59. doi: 10.1128/AAC.04942-14. Epub 2015 May 11.
4
5
Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine.甲氟喹抗疟活性的药代动力学-药效学建模。
Parasitology. 2001 Oct;123(Pt 4):337-46. doi: 10.1017/s003118200100854x.
6
[Resistance to the antimalarial drugs].[对抗疟药物的耐药性]
Rev Esp Quimioter. 2016 Sep;29 Suppl 1:72-5.
7
Identification of a new chemical class of antimalarials.鉴定新型抗疟药物化学结构。
J Infect Dis. 2012 Sep 1;206(5):735-43. doi: 10.1093/infdis/jis418. Epub 2012 Jun 25.
8
Malaria-Update on Antimalarial Resistance and Treatment Approaches.疟疾——抗疟药耐药性及治疗方法的最新情况
Pediatr Infect Dis J. 2018 Apr;37(4):367-369. doi: 10.1097/INF.0000000000001887.
9
Design and synthesis of amidoxime derivatives for orally potent C-alkylamidine-based antimalarial agents.设计并合成酰胺肟衍生物，用于口服有效的基于 C-烷基脒的抗疟药物。
Bioorg Med Chem Lett. 2009 Feb 1;19(3):624-6. doi: 10.1016/j.bmcl.2008.12.058. Epub 2008 Dec 24.
10
Curcumin for malaria therapy.用于疟疾治疗的姜黄素。
Biochem Biophys Res Commun. 2005 Jan 14;326(2):472-4. doi: 10.1016/j.bbrc.2004.11.051.
引用本文的文献
1
The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: A pooled analysis of individual participant data.青蒿素联合疗法、非青蒿素疗法及8-氨基喹啉抗疟疗法的传播阻断活性：个体参与者数据的汇总分析
PLoS Med. 2025 Aug 14;22(8):e1004683. doi: 10.1371/journal.pmed.1004683. eCollection 2025 Aug.
2
Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance.在青蒿素部分耐药的情况下鉴定新一代抗疟三氧杂环已烷。
Sci Adv. 2025 Aug 8;11(32):eads9168. doi: 10.1126/sciadv.ads9168.
3
Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission.疟原虫环核苷酸磷酸二酯酶抑制剂可阻断无性血液期发育及蚊虫传播。
Sci Adv. 2024 Dec 6;10(49):eadq1383. doi: 10.1126/sciadv.adq1383.
4
Artemisinin-resistant malaria.抗青蒿素疟疾
Clin Microbiol Rev. 2024 Dec 10;37(4):e0010924. doi: 10.1128/cmr.00109-24. Epub 2024 Oct 15.
5
Diagnosis and management of malaria in the intensive care unit.重症监护病房中疟疾的诊断与管理
J Intensive Med. 2023 Nov 3;4(1):3-15. doi: 10.1016/j.jointm.2023.09.002. eCollection 2024 Jan.
6
Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria.直肠用青蒿琥酯栓剂治疗疑似重症疟疾的转诊前治疗。
PLoS Med. 2023 Nov 9;20(11):e1004312. doi: 10.1371/journal.pmed.1004312. eCollection 2023 Nov.
7
Promoter variations in DBR2-like affect artemisinin production in different chemotypes of .DBR2样基因的启动子变异影响不同化学型青蒿素的产生。 （你提供的原文似乎不完整，“in different chemotypes of.”后面缺少具体内容）
Hortic Res. 2023 Aug 16;10(9):uhad164. doi: 10.1093/hr/uhad164. eCollection 2023 Sep.
8
Assessment of the transmission blocking activity of antimalarial compounds by membrane feeding assays using natural Plasmodium falciparum gametocyte isolates from West-Africa.采用源自西非的天然疟原虫配子体分离物，通过膜饲养测定评估抗疟化合物的传播阻断活性。
PLoS One. 2023 Jul 26;18(7):e0284751. doi: 10.1371/journal.pone.0284751. eCollection 2023.
9
Therapeutic efficacy of pyronaridine-artesunate (Pyramax) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia.吡喹酮-青蒿琥酯（Pyramax）治疗埃塞俄比亚西北部哈穆西特健康中心无并发症恶性疟原虫感染的疗效。
Malar J. 2023 Jun 17;22(1):186. doi: 10.1186/s12936-023-04618-y.
10
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Viability after Antimalarial Treatment In Vitro.疟原虫减少率（PRR）检测版本2：体外抗疟治疗后活力的标准化评估
Pharmaceuticals (Basel). 2023 Jan 23;16(2):163. doi: 10.3390/ph16020163.
本文引用的文献
1
The Surgery of Arterial Disease and Injury.动脉疾病与损伤的外科手术
Br Med J. 1946 Jan 5;1(4435):1-4.
2
Chronotherapy of malaria: an approach to malaria chemotherapy.疟疾的时间疗法：一种疟疾化疗方法。
Parasitol Today. 1991 Dec;7(12):350-2. doi: 10.1016/0169-4758(91)90218-d.
3
4
A contribution to the problem of strains of human plasmodium.对人类疟原虫菌株问题的一项贡献。
Riv Malariol. 1954 Jun;33(1-3):1-21.
5
Daraprim resistance in experimental malarial infections.实验性疟疾感染中的达拉匹林耐药性。
Nature. 1952 Sep 6;170(4323):415. doi: 10.1038/170415a0.
6
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.阿托伐醌单独或与其他抗疟药物联合用于治疗泰国急性非复杂性疟疾的临床研究。
Am J Trop Med Hyg. 1996 Jan;54(1):62-6. doi: 10.4269/ajtmh.1996.54.62.
7
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria.
Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):660-4. doi: 10.1016/0035-9203(95)90435-2.
8
Iron chelation as a chemotherapeutic strategy for falciparum malaria.铁螯合作为恶性疟原虫疟疾的一种化疗策略。
Am J Trop Med Hyg. 1993 Feb;48(2):193-7. doi: 10.4269/ajtmh.1993.48.193.
9
Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.实验性感染模型中的抗生素后效应：与体外现象及人类感染治疗的关系
J Antimicrob Chemother. 1993 May;31 Suppl D:149-58. doi: 10.1093/jac/31.suppl_d.149.
10
Anti-TNF therapy inhibits fever in cerebral malaria.抗TNF治疗可抑制脑型疟疾中的发热。
Q J Med. 1993 Feb;86(2):91-8.
Zotero 插件